Genefitletics Enhances Platform to Decode Cellular Health
Indian biotech startup Genefitletics has unveiled a major update to its health platform, enabling it to assess the condition of individual cells by detecting the expression of key biological signals. This advancement allows for early identification of chronic diseases—often in their asymptomatic stages—through a combination of next-generation sequencing and machine learning. According to the company, the upgraded platform now generates a “cellular health score” by analyzing markers linked to inflammation, mitochondrial function, immune activity, cellular stress, and senescence. This empowers users to monitor and improve their internal health at the cellular level. Additional capabilities include evaluations related to triglyceride regulation, risk indicators for irritable bowel disease, and a dynamic feedback system that shows how nutritional and lifestyle interventions influence biological pathways in real time. Sushant Kumar, Founder and CEO of Genefitletics, explained, “Our proprietary platform, PROTEBA, is trained on an extensive dataset—over 12 billion molecular data points, 45 million phenotype records, more than 35,000 peer-reviewed scientific publications, and continuously updated clinical insights. It now enables us to track the activity of biological pathways involved in cellular inflammation, energy inefficiency, aging, and various types of cellular stress—including oxidative, genotoxic, hypoxia-induced, and protein-misfolding stress.” This update marks a significant leap in personalized health monitoring, providing deeper insight into cellular functions and the impact of daily choices on long-term health. Source: ETHealthWorld
Genefitletics Enhances Platform to Decode Cellular Health Read More »